

Solutions for Radiolabeled ADME Studies

XenoFinder Overview

XenoFinder is a specialized Contract Research Organization (CRO) providing expert drug biotransformation and radiolabeled ADME services globally. We support every stage of drug discovery, development, and regulatory submission.

With state-of-the-art facilities, advanced LC-HRMS data processing technology, and a team of seasoned scientists, XenoFinder delivers high-quality, customized study solutions for both small molecule drugs and novel therapeutic modalities—including ADCs, PROTACs, peptides, covalent drugs and oligonucleotides.

Radiolabeled ADME Study Services

Radiolabeled Compound Synthesis:

High-quality synthesis, purification, and delivery of radiolabeled molecules via our trusted partners.

In Vitro Metabolism Studies:

Metabolite profiling using liver microsomes, hepatocytes, and other systems.

Animal Radiolabeled ADME Studies:

Small Molecule Drugs:

Mass balance and metabolite profiling in intact and bile duct-cannulated (BDC) mice, rats, dogs, and monkeys.

New Drug Modalities:

Metabolite exposure and clearance pathway characterization of oligonucleotides, peptides, and payloads in mice, rats, dogs, and monkeys.

Tissue Distribution Studies:

Radioactivity and metabolite profile determination in various animal tissues.

QWBA Analysis:

Radioactivity distribution assessment in whole body of rodents

Human Mass Balance Studies:

Total radioactivity and metabolite profile evaluation in plasma, urine, and feces. Metabolite exposure and metabolic clearance pathway characterization

Covalent Binding Studies:

Evaluation of drug binding to macromolecules.

Why Choose XenoFinder?

Deep Experience & Proven Expertise

- Leadership team of trained biotransformation scientists.
- Over 150 publications in DMPK and LC-MS applications.
- Proven track record in both pharma and CRO settings.
- Specialization in metabolite structural elucidation and radiolabeled ADME studies.

Tailored, Client-Focused Approach

- Studies designed around your specific goals.
- Commitment to scientific integrity, fast timelines, and cost-effective delivery.

Proprietary LC-HRMS Data Processing

- Advanced Background Subtraction Filter (BSF) software.
- Enables untargeted metabolite detection and identification of small molecule drugs and new therapeutic modalities

Radiolabeled ADME Research Publications by XenoFinder Scientists

- A mass balance study of ^{14}C -SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans. *Frontiers in Pharmacology*, 2023
- Absorption, Distribution, Metabolism, and Excretion of ^{14}C -BS1801, a Selenium-Containing Drug Candidate, in Rats. *Molecules*, 2023
- Pharmacokinetics, mass balance, and metabolism of ^{14}C -TPN171 in humans. *Acta Pharmacologica Sinica*, 2023
- ADME of ^{14}C -Mefuparib (CVL218), a PARP1/2 inhibitor, in rats. *Cancer Chemotherapy and Pharmacology*, 2022
- Metabolic disposition of ^{14}C -abivertinib: Role of glutathione conjugation. *British Journal of Clinical Pharmacology*, 2021
- Pharmacokinetics and metabolism of ^{14}C -vicagrel in humans. *Acta Pharmacologica Sinica*, 2021
- Disposition of ^{14}C -brasofensine in rats, monkeys, and humans. *Drug Metabolism and Disposition*, 2008
- Applications of liquid radiochromatography in drug metabolism. In: *Drug Metabolism in Drug Design and Development*, Wiley, 2007
- Analysis of low-level radioactive metabolites in biological fluids. *Journal of Pharmaceutical and Biomedical Analysis*, 2005

Contact Us

USA: Dr. Mingshe Zhu
mingshe.zhu@xenofinder.com

China: Dr. Chongzhuang Tang
chongzhuang.tang@xenofinder.com

www.xenofinder.com
Radiolabeled ADME Lab: 108 Yuxin Road, Suzhou Industrial Park, China